‹ Eli Lilly
Ch 4 · The Bet on Obesity
Chapter 4 · Management
Lilly bet on obesity before it was obvious.
CEO David Ricks pushed research and factory-building years ahead of the boom.
↓ scroll to read
✦ The bottom line
David Ricks, CEO since 2017, steered Lilly's bet on diabetes-and-obesity science and pre-built manufacturing — so when demand exploded, Lilly was ready when others weren't.
↓ the brief below
The decade-long bet
1876
Founded by Eli Lilly; widely held today — no single controlling owner.
2017
David Ricks becomes CEO and leans into incretin (GLP-1) science.
2018-22
Invests early in manufacturing capacity — a bet on demand that hadn't arrived.
Now
The capacity bet pays off; Lilly refills its pipeline with bolt-on acquisitions.
Confidence, measured · raised guidance
$85
B
After a strong quarter, management raised full-year 2026 revenue guidance by $2B, to $82-85B — a vote of confidence in both demand and supply.
Source · 8-K · Item 2.02 — 2026 Financial Guidance · FY2026 guidance · Filed Apr 30, 2026
Putting the windfall to work
Business development activity included the agreements to acquire Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics … continued investing in Lilly's future growth through four acquisitions.
↳ Management isn't just harvesting today's hit — it's buying the science for the next one. Four biotech deals in a single quarter is reinvestment, not coasting.
Source · 8-K · Item 2.02 — CEO commentary & business development · Q1 2026 · Filed Apr 30, 2026
✓
Strong
A decade of early bets on obesity science and capacity — now paying off, and reinvested.
You just finished
Chapter 4 · MANAGEMENT
The Bet on Obesity
you now read: skin in the game
Up next
Then
Chapter 6 · RISK
One Molecule, Two Threats